Abstract
Introduction
Amiodarone is frequently used to control atrial fibrillation (AF) -the most common arrhythmia [1, 2] . Because each amiodarone molecule contains two iodine atoms with about 10% dissociating into free iodine [3] , long-term use of amiodarone may lead to abnormal thyroid function in 15-20% of patients [4] , seriously impairing further drug treatment for AF. Although paroxysmal AF refractory to oral antiarrhythmic drugs is a class I indication of catheter ablation now commonly used for maintenance of sinus rhythm [5] , studies are lacking on its safety and efficacy in patients with frequent and symptomatically intolerable paroxysmal AF complicated with amiodarone-induced thyrotoxicosis (AIT), which is the subject of the present study.
Methods

Case selection
From 146 consecutive patients with paroxysmal AF as per the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guideline who underwent ablation at the Affiliated Hospital of Qingdao University from January 2013 to June 2014, 20 (11 males/9 females; mean age 63.65 ± ± 8.91 years) with frequent and symptomatically intolerable paroxysmal AF complicated with AIT were selected as the AIT group, while other 30 (17 males/13 females; mean age 60.67 ± 8.54 years) who also received oral amiodarone but continued to have normal thyroid function were randomly selected as the control group. AIT was diagnosed in patients who had normal thyroid function and after taking amiodarone had a thyroid stimulating hormone (TSH) level < 0.27, free thyroxine (FT4) level > 22, and/or free triiodothyronine (FT3) level > 6.8 (normal values, TSH: 0.27~4.2 IU/mL; FT4: 12.0~22.0 pmol/L; FT3: 3.10~6.80 pmol/L) [6] . Patients with any of the following conditions were excluded from the AIT group: AF found at the same time or after thyrotoxicosis occurrence; evidence of organic thyroid disease in thyroid ultrasound; presence of antithyroid peroxidase (ATPO) antibody and anti-thyroglobulin antibody (TG-Ab); persistent AF; structural heart diseases, such as valvular heart disease and congenital heart disease; and presence of left atrial thrombus in transesophageal echocardiography. Before taking amiodarone, all patients underwent laboratory testing for FT3, FT4, TSH, ATPO, TG-Ab, and thyroid ultrasound; while on amiodarone, thyroid function was checked every 3 months; amiodarone was withdrawn as soon as thyrotoxicosis was found, and catheter ablation was planned; all patients (including AIT and control groups) stopped amiodarone and received pulmonary vein isolation (PVI) in 3 days; 4 patients with severe thyrotoxicosis received methimazole before ablation and the other 16 patients in AIT group did not receive any treatment. Before circumferential pulmonary vein isolation (CPVI) all patients: underwent laboratory testing for FT3, FT4, TSH, ATPO, and TG-Ab 48 h pre procedure; received the anticoagulant warfarin, which was not stopped before PVI if the international normalized ratio (INR) was between 2 and 3; and were assessed 24 h pre procedure with esophageal ultrasonography to exclude left atrial thrombus.
All the patients had signed a general written informed consent. Ethical approval was given by the medical Ethics Committee of the Affiliated Hospital of Qingdao University. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Mapping and ablation
After left subclavian vein puncture, a 10-electrode electrophysiology catheter was placed in the coronary sinus (CS); after 2 atrial septal punctures, two 8.5 F Swartz long sheaths (SL1) were placed in the left atrium; changes in pulmonary vein potential were recorded with a LASSO catheter; under the guidance of the Carto system, a 3.5 mm ablation catheter (Navi-Star ThermoCool, Biosense-Webster, USA) was used for left atrial reconstruction and CPVI of the bilateral pulmonary veins; at the anterior wall, the discharge energy was 35 W; at the top and rear walls, the discharge energy was 30 W; at each ablation point, the discharge lasted 20 s or the potential was decreased by 80%; and the 2-way bilateral PVI was performed as previously published [7, 8] . After CPVI, the patient was observed for 30 min; isoproterenol via intravenous drip then was given to increase the heart rate up to 120 bpm. Burst artial pacing was performed from CS at a circle length from 300 ms to 200 ms to observe whether there was atrial tachycardia, atrial flutter, or AF episodes, and whether there occurred recovery of conduction (RoC) of pulmonary vein potential.
Postoperative care and follow-up
After catheter ablation, oral warfarin was prescribed for at least 3 months, with dose adjustment to maintain the INR between 2 and 3.
www.cardiologyjournal.org Anticoagulation was extended beyond 3 months if AF relapsed. After PVI, none of the patients received any antiarrhythmic drugs. For patients in the AIT group with severe thyrotoxicosis, upon consultation with endocrinologists, methimazole was given. The following parameters were captured: (1) Perioperative complications such as cardiac tamponade, embolization, and hematoma; (2) Operation time and X-ray exposure time; (3) Whether arrhythmia was induced and whether there was RoC of pulmonary vein potential after isoproterenol administration; (4) The recurrence rate of atrial tachyarrhythmia after PVI: surface electrocardiogram (ECG) and dynamic ECG were recorded at each month during 12-month followup or at the time the patient perceived recurrence to determine if it was symptomatic AF, typical atrial flutter, or other atrial tachyarrhythmia. AF was defined according to 2014 AHA/ACC/HRS guidelines. We have defined typical atrial flutter as cavotricuspid isthmus-dependent atrial flutter, atrial rate 250-350/min. Other atrial tachyarrhythmia was defined as atypical atrial flutter or atrial tachycardia. The former refers to non-cavotricuspid isthmus-dependent atrial flutter, atrial rate 250--350/min; the latter refers to atrial tachyarrhythmia with atrial rate 150-250/min, whose mechanism is reentrant or focal. Recurrence could be defined if a monitored episode of atrial arrhythmia lasted over 30 s. If the recurrence occurred within 3 months after PVI, it was defined as early recurrence and if beyond 3 months as late recurrence [9] .
Statistical analysis
All the continuous variables are expressed as mean ± standard deviation and were compared with single factor analysis of variance, while categorical variables are expressed as number and percentage and were compared using the c 2 test. Statistical analyses were performed using SPSS19.0 statistical software. P < 0.05 was considered statistically significant.
Results
Distribution of baseline sociodemographic and clinical characteristics, including gender, age, left atrial dimension, AF duration, and procedural characteristics (Table 1) .
In the AIT group, isoproterenol infusion 30 min after PVI induced: 1) AF in 7 (35%) cases: 3 from the superior vena cava (SVC) terminated after SVC isolation [10] , 2 were associated with RoC of pulmonary vein conduction, and were terminated by ablation at areas with RoC along the PVI ablation line, and 2 were neither associated with the SVC nor with RoC of pulmonary vein conduction, and were treated with electrical cardioversion; 2) Atypical atrial flutter or atrial tachycardia in 3 (15%) cases: 1 left atrial roof-dependent macroreentrant flutter, which was terminated by linear ablation at the left atrial roof, validated by 2-way block of atrial top line [11, 12] ; 1 mitral isthmus-dependent macroreentrant flutter, which was terminated by linear ablation at the mitral isthmus, with the ablation being continued until there was 2-way block of the mitral isthmus line [11, 12] ; and 1 associated with atrial-pulmonary vein potential conduction gap, which was terminated by gap ablation along the PVI ablation line; 3) Typical atrial flutter in 3 (15%) cases, all tricuspid isthmus-dependent which were treated with tricuspid isthmus ablation. In the AIT group, 3 (15%) cases showed recovery of atrium-pulmonary vein potential conduction: 2 cases led to AF and 1 case led to atrial tachycardia.
In the control group, AF from SVC was induced in 1 (3.33%) case, which was terminated after SVC isolation; atrial tachycardia from the gap along the PVI ablation line was induced in 2 (6.67%) cases, which were terminated after gap ablation; typical atrial flutter was induced in 1 case, which was treated with tricuspid isthmus ablation. There were 9 (30%) cases of atrium-pulmonary vein potential conduction recovery, in which atrial tachycardia was induced in 2 cases, and no atrial arrhythmia was induced in 7 cases.
Non-pulmonary vein-related atrial tachyarrhythmia was significantly more often induced in the AIT group (10 [50%] cases: 5 AF, 3 atrial flutter, and 2 atrial tachycardia cases) than in the control group (1 AF [3.33%] case). Early but not late recurrence rate of atrial tachyarrhythmia was significantly higher in the AIT than in the control group, with significant differences at every month up to 3 months (Table 2) .
Before PVI, the levels of thyroid hormones were as follows: FT3 (minimum 6.47, maximum 13.57, average 7.78 ± 1.61 pmol/L), FT4 (minimum 22.53, maximum 60.26, average 30.43 ± ± 8.23 pmol/L), and TSH (minimum 0.005, maximum 0.261, average 0.116 ± 0.091 IU/mL). Among the 20 patients with AIT, 4 patients with severe AIT were treated with methimazole as per endocrinologist's advice after PVI. Thyroid function was higher at the time of ablation, and returned to normal in 1, 2, and 1 cases at 1, 2, and 3 months after PVI, respectively. In other 16 patients who did not take the anti-hyperthyroidism drug, thyroid function returned to normal in 10, 4, and 2 cases at 1, 2, and 3 months after PVI, respectively, which is consistent with the report by Bartalena et al. [13] who documented that thyroid function returns to normal from 1 to 3 months in AIT patients [13] [14] [15] .
Discussion
In the present study, 20 patients with paroxysmal AF complicated with AIT underwent radiofrequency ablation therapy to treat frequent symptomatic episodes, and as compared to matched controls with normal thyroid function, had significantly more often isoproterenol-induced AF and non-pulmonary vein-related atrial tachyarrhythmias, and significantly higher rates of early recurrence of atrial tachyaarhythmia.
Higher rates of isoproterenol-induced arrhythmias may be secondary to high thyroid hormone levels, which can: 1) Inhibit the inward L type calcium channel, increase the outgoing potassium current, shorten the action potential plateau period, and Data are presented as mean ± standard deviation or n (%); AIT -amiodarone-induced thyrotoxicosis increase the repolarization speed, thereby shortening action potential duration, effective responding period, and reentrant wavelength in the atria, and resulting in tiny reentrant waves [16] ; 2) Alter the atrial distribution of autonomic nerves, cause over-allocation of atrial sympathetic nerves and autonomic dysfunction, and increase atrial arrhythmia incidence; 3) Significantly increase the autorhythmicity of atrial evoked potential [17] , causing AF as well as atrial flutter and atrial tachycardia. The abovementioned features also might underlie the higher early recurrence rates of atrial tachyarrhytmia in the AIT group, which also might be related to local edema after CPVI because of the impact of ablation energy on local tissues. Bertaglia et al. [18] reported that within 3 months after ablation for patients with AF, 46% of patients had atrial arrhythmias, most of which spontaneously resolved 3 months later.
In order to decrease the recurrence rate of AIT patients, we spent more operation time in the AIT group (AIT group vs. control group, 170.60 ± ± 14.80 min vs. 158.18 ± 9.06 min), which may result in lower RoC of the pulmonary veins when intravenously treated with isoprenaline. Nevertheless, no significant difference was found between the two groups (p = 0.191). In fact, all patients had no RoC of the veins at the moment the operation finished. We examined the rate of RoC of the pulmonary veins during operation, but the recurrence rate of atrial tachyarrhythmias in AIT patients was examined after operation. During the first 3 months, we cannot examine the rate of RoC after operation, the thyroid hormone levels can affect the percentage of recurrence.
Within 3 months, thyroid hormone levels were high and normalized thereafter. Thus, the high recurrence 3 months post ablation was likely due to residual mild hyperthyreosis. The thyroid hormone levels of both the AIT group and the control group were normal after 3 months post ablation, which resulted in similar recurrence.
The present study found that after 3 months post CPVI, when the thyroid function returned to normal, the late success rate was similar in both groups. Auer et al. [19] had reported an AF incidence of 13.8% in patients with primary hyperthyroidism, and 5 times that of the general population in patients with subclinical hyperthyroidism. When thyroid function returns to normal, the effects of the thyroid hormone on the atria fade away with most associated AF resolving [19] . In a previous study, for patients with primary hyperthyroidism, after thyroid function returned to normal but still had AF, ablation success rate was similar to that of AF patients without hyperthyroidism [20] . The latter result as well as those in the present study indicate that after thyroid hormone levels return to normal, AF is associated with only focal evoking loci.
In this study, after PVI, the late recurrence rate of atrial tachyarrhythmias was lower than early recurrence rate, and similar to that of paroxysmal AF patients with normal thyroid function. Possible reasons for the latter observation include: (1) In the AIT group, hyperthyroidism was not very severe, with thyroid function returning to normal in both 16 of 20 patients 3 months after amiodarone discontinuation or with addition of methimazole for 3 months in the remaining 4 with more severe AIT; (2) Intraoperative isoproterenol via intravenous drip induced atrial flutter, AF, and atrial tachycardia unrelated to pulmonary vein potential, reducing the relapse of atrial arrhythmia after catheter ablation [21] ; (3) After PVI, observation for 30 min, and isoproterenol via intravenous drip, the gap along the PVI ablation line was treated with ablation, reducing the atrial tachyarrhythmias secondary to recovery of atrium-pulmonary vein conduction [21] .
Limitations of the study
Interpretation of the findings in the present study is limited by its single-center, retrospective design with a small sample size and by the fact that hyperthyroidism was mild among studied patients with paroxysmal AF complicated with AIT. Recurrence rates in patients with paroxysmal AF complicated with severe AIT warrant further studies.
Conclusions
For patients with paroxysmal AF complicated with AIT, early ablation appears safe and effective when performed under the guidance of a 3-dimensional mapping system, with 30 min observation and use of isoproterenol and pacing to induce atrial tachyarrhythmias related to pulmonary vein and extra-pulmonary vein for ablation.
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